Orforglipron (LY3502970)
Eli Lilly once-daily, SMALL-MOLECULE ORAL GLP-1 receptor agonist (LY3502970). Phase 3 obesity (ATTAIN) + T2DM (ACHIEVE) ongoing. FDA approval expected 2026-2027. NOT a peptide – oral alternative to the classic injectable GLP-1 RAs (Semaglutide, Liraglutide).
WHAT IS ORFORGLIPRON (LY3502970)?
Detailed overview
Orforglipron (LY3502970) is Eli Lilly's once-daily, small-molecule oral GLP-1 receptor agonist. Structurally it is NOT a peptide – a small organic molecule that activates the GLP-1 receptor in a biased-agonist fashion, exclusively along the Gs pathway, bypassing β-arrestin. This explains the clinical profile: efficacy on body weight + HbA1c, smaller GI side-effect incidence than injectable peptide GLP-1 RAs (Semaglutide, Liraglutide). The Phase 2 ATTAIN-1 trial (Wharton 2023 NEJM PMID 37356087) showed ~14.7% body-weight reduction in the high-dose arm over 36 weeks in obesity patients – comparable to injectable Semaglutide 2.4 mg/week STEP-1 (~14.9% over 68 weeks). Phase 2 T2DM (Frías 2023 NEJM PMID 37356866) HbA1c reduction ~2.0% over 26 weeks. In 2026 the Phase 3 ATTAIN-1 (obesity) + ATTAIN-2 (obesity + T2DM) + ACHIEVE-1 (T2DM) trials are ongoing; NDA filing expected mid-2026. Competitors: Pfizer Danuglipron (Phase 2-3, hepatic stress concern), Roche CT-388 and Structure Therapeutics GSBR-1290 (oral peptide-mimetics).
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Gastrointestinal effects (nausea, vomiting, diarrhea, abdominal discomfort), especially during dose titration; these are dose-dependent and the most common adverse events, though with somewhat lower incidence than injectable peptide GLP-1 RAs.
- Decreased appetite and early satiety with associated weight loss; this is partly mechanism-related but can also lead to unwanted degree of weight and lean-mass loss.
- Risk of hypoglycemia when combined with insulin or a sulfonylurea (on its own the GLP-1 RA glucose-dependent action makes hypoglycemia risk low).
- Headache, fatigue, and dizziness in the early phase of treatment.
- Acute pancreatitis is a rare but potentially serious risk, as with GLP-1 receptor agonists generally; persistent, severe abdominal pain radiating to the back requires immediate medical evaluation.
- Gallbladder disease (gallstones, acute cholecystitis), which may be related both to rapid weight loss and to the GLP-1 effect.
- Marked fullness, reflux, and occasionally altered absorption of orally taken medicines due to slowed gastric emptying.
Contraindications · 3
- History of medullary thyroid carcinoma (MEN-2 syndrome) – class effect for all GLP-1 RAs
- History of pancreatitis (relative)
- Severe gastroparesis
Studies
Related research and clinical findings
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
Wharton S, Aronne LJ, Stefanski A
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Frías JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, Kazda C, Mather KJ, Haupt A, Pratt E, Dunn J, Robins D, Karanikas C, Thomas MK
Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Cost.
Patel D
Telegram
Have a question about Orforglipron (LY3502970)?
Educational drug info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation or the SmPC. Talk to your doctor!
The information here is for educational and scientific purposes only. Medication use requires medical consultation and a prescription. The indications, dose ranges, and side effects listed here do NOT replace the official Summary of Product Characteristics (SmPC) or consultation with a physician. Do not start or stop any medication on your own. In an emergency, call your local emergency number.